BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2817713
Number of visits today
1088
Number of downloads
2067123
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Yao Z, Gao G, Yang J, Long Y, Wang Z, Hu W, Liu Y. Prognostic Role of the Activated p-AKT Molecule in Various Hematologic Malignancies and Solid Tumors: A Meta-Analysis. Front Oncol 2020;10:588200. [PMID: 33363017 DOI: 10.3389/fonc.2020.588200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jin Y, Qiu L, Bao W, Lu M, Cao F, Ni H, Zhao B. High expression of IGHG1 promotes breast cancer malignant development by activating the AKT pathway. Cell Cycle 2023;22:718-31. [PMID: 36404682 DOI: 10.1080/15384101.2022.2147141] [Reference Citation Analysis]
2 Liu Y, Cheng H, Cheng C, Zheng F, Zhao Z, Chen Q, Zeng W, Zhang P, Huang C, Jiang W, Liu X, Liu G. ZNF191 alters DNA methylation and activates the PI3K‐AKT pathway in hepatoma cells via transcriptional regulation of DNMT1. Cancer Medicine. [DOI: 10.1002/cam4.4535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wu Q, Liu TY, Hu BC, Li X, Wu YT, Sun XT, Jiang XW, Wang S, Qin XC, Ding HW, Zhao QC. CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways. Front Oncol 2021;11:717626. [PMID: 34395292 DOI: 10.3389/fonc.2021.717626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Degan SE, Gelman IH. Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways. Mol Cancer Res 2021;19:1251-7. [PMID: 33931488 DOI: 10.1158/1541-7786.MCR-20-1066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345